A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor Read more about A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain Read more about Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study) Read more about Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer Read more about Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
VE303 for Prevention of Recurrent Clostridioides Difficile Infection Read more about VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome Read more about Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer Read more about Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) Read more about A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis Read more about A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Read more about Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck